(VIANEWS) – At 11:10 EST on Friday morning, FibroGen (NASDAQ: FGEN) shares were down 13.5% to EUR2.05, following five straight sessions of increases. Still, the overall NASDAQ was up by 0.73% at EUR15,473.61, suggesting an overall upward trend. FibroGen had closed at EUR2.37 last week – 90.77% lower than its 52-week high of EUR25.69.
About FibroGen
FibroGen, established in 1993, specializes in developing therapeutics to address unmet medical needs. FibroGen’s lead product candidates include Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor currently in Phase III clinical development for treating idiopathic pulmonary fibrosis, pancreatic cancer and Duchenne muscular dystrophy; Roxadustat is an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity which has completed Phase III trials for anemia associated with chronic kidney disease in multiple countries as well as myelodysplastic syndromes; FifibroGen has collaboration agreements with Astellas Pharma Inc and AstraZeneca AB to support development of these products; it is headquartered in San Francisco California
Yearly Analysis
Investment Outlook of FibroGen Inc. (FGNA)
Overview: FibroGen Inc is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies to address serious unmet medical needs. As of press time the stock was trading at EUR2.05, significantly below its 52-week high of EUR25.69 but above its 52-week low of EUR0.33.
Yearly Top and Bottom Values:
Annual top and bottom values provide invaluable insights into a stock’s performance in the market. At present, FibroGen stock is trading at a significant discount to its 52-week high price, providing investors with an opportunity to buy at lower cost; yet its 52-week low value indicates positive momentum for this company in its performance in the market.
Anticipated Sales Growth:
FibroGen’s sales growth projection for this year is anticipated at 15.2%, which indicates positive revenue trends. Their projected growth for next year, however, may be more modest – potentially raising concerns if its performance and prospects decline substantially before making investment decisions.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA):
FibroGen has achieved an EBITDA score of 1.67 which indicates it is producing positive earnings before accounting for interest, taxes, depreciation, amortization or any other costs related to its operations such as interest payments or amortization charges. A positive EBITDA indicates profitability as well as a healthy financial status of the company – however it’s essential to also take other metrics such as net income, operating cash flow or balance sheet data so as to gain a full picture.
Outlook:
FibroGen’s stock appears undervalued on paper; however, investors must carefully consider other financial metrics and the company’s growth prospects prior to making any definitive investment decisions. Likewise, investors should pay attention to any news or developments regarding either FibroGen itself or biopharmaceutical industry as it could influence performance of its shares.
Technical Analysis
FibroGen stock price has experienced an unexpected and drastic drop, currently trading at EUR1.55, well below both its 50-day moving average of EUR0.69 and 200-day moving average of EUR5.32. Additionally, reported volume is 67.02% higher than its usual level at 2,476,6880 which indicates high trading activity.
FibroGen’s intraday variation average for the past week, month, and quarter has been 6.11%; these values correspond with its highest amplitudes in volatility at 6.11% for its highest averages for last week, month and quarter respectively.
According to the stochastic oscillator, FibroGen stock is currently considered “oversold,” suggesting it could be an ideal time for investors to purchase this share. Before making any definitive investment decisions however, investors should carefully evaluate their strategies and conduct proper research prior to making decisions on purchases or sales of stock.
Quarter Analysis
FibroGen has had an outstanding financial performance in 2018. Their revenue growth over the last year is remarkable: an astonishing year-on-year quarterly revenue growth rate of 155.1. Additionally, sales growth was 9.2% this quarter and 16.4% next quarter according to sales forecast. FibroGen projected growth estimates are 37.1 and 46.9% for both quarters respectively indicating its strong trajectory for growth.
Equity Analysis
Earnings per Share (EPS) is a measure of company profitability determined by dividing its net income by the number of outstanding shares. A negative EPS value indicates a loss for the last 12 months; in this instance, FibroGen recorded a trailing twelve month EPS value of EUR-3.06 which indicates this reality – this may provide investors with useful information in deciding whether or not they invest in FibroGen.
More news about FibroGen (FGEN).
